Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By / / Building & Construction / 1 minute of reading


Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Gam1983/Getty Images



Source link

About The Author

Avatar of Cindy Miller
Cindy Miller is a writer who covers politics, health, business, and finance. She has been writing for Gibbs Press news site] since 2018 and has won several awards for her work. She likes to spend her free time reading and practicing yoga. She also enjoys cooking and traveling.

Start typing and press enter to search

Scroll to Top